Researchers have identified 39 genes as critical to idiopathic pulmonary fibrosis (IPF), based on a computational analysis of large genomic studies. Their study, “Detecting the Molecular System Signatures of Idiopathic Pulmonary Fibrosis through Integrated Genomic Analysis,” appeared in the journal Scientific Reports. IPF patients do not respond to anti-inflammatory therapies such…
IPF May Have a Specific Gene Signature, Aiding Potential New Therapies, Analysis Finds
What Is a ‘Spoonie’?
https://www.youtube.com/watch?v=n2YQ3H4XT3c If you’re active on the Internet, particularly in groups and forums regarding chronic illness, you’ve definitely noticed the term “spoonie” being thrown around. MORE: While there is currently no known cure for IPF, there are treatments available to help ease the symptoms. Spoonie is a…
Veracyte will present new information supporting the use of its genomic tests to diagnose idiopathic pulmonary fibrosis (IPF) and lung cancer at the American Thoracic Society 2017 International Conference in Washington, May 19-24. The Envisia and Percepta Bronchial Genomic Classifiers were designed to reduce the need for diagnostic surgery and to…
It only takes a moment for someone to Google pulmonary fibrosis (PF) to discover a list of unpleasant symptoms that accompany this disease. Some of the most common symptoms include shortness of breath with exertion, dry cough and fatigue. As you may imagine, there are many other…
7 Common Questions About Esbriet
Esbriet (pirfenidone) is an anti-fibrotic and anti-inflammatory drug used in the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF). Manufactured by Genentech and given FDA approval in 2014, the drug reduces the amount of lung fibrosis by blocking secretions responsible for excessive collagen production. It also reduces inflammation in the lungs.
The anti-inflammatory molecule protectin DX (PDX) has been shown to improve pulmonary fibrosis (PF) and lung function in mice, new research shows. The study, “Posttreatment with Protectin DX ameliorates bleomycin-induced pulmonary fibrosis and lung dysfunction in mice,” was published in the journal Scientific Reports. Lung fibrosis is characterized…
Being diagnosed with a chronic lung disease like pulmonary fibrosis can be overwhelming, and patients often feel isolated and alone. MORE: What you need to know about Esbriet. This was exactly how Debra Baldwin felt after she was diagnosed with pulmonary fibrosis in 2015. According to Fox8, the Burlington,…
Two months ago, I took a bold step to ask for help My husband and I had just returned from a trip to southern California to visit our family. We drove the 800-mile round trip, breaking it up into 200 miles per day because I get so exhausted…
8 of the Most Common Lung Diseases in Women
There are many different lung diseases that vary in severity, but one thing is certain: the number of women developing and dying from lung diseases is rapidly rising in the U.S. With early diagnosis comes early treatment which can help prevent the disease from progressing too quickly. Here are some of the most common lung diseases affecting…
Esbriet Lowers Risk of Respiratory Hospitalizations Among IPF Patients by Nearly Half, Study Finds
Besides its other benefits, Esbriet (pirfenidone) prevents respiratory-related hospitalizations in patients with idiopathic pulmonary fibrosis (IPF), according to a study examining data from more than 1,200 patients. Findings also showed that hospitalized patients who took Esbriet were less likely to die after one year. This effect decreased over time, though researchers…
Your PF Community
Recommended Posts
- How we manage the long commute to my IPF doctor appointments
- In preparing for emergencies, we’re using technology to our advantage
- US, EU regulators name deupirfenidone an orphan drug for treating IPF
- This month is our time to raise awareness about rare diseases
- Targeting ‘overlooked’ gene could lead to new treatments for IPF: Study
